Drugs for children with hypercholesterolemia: Be cautious

Journal of Pediatric Endocrinology and Metabolism

Volumn 22, Issue 6, 2009, Pages 483-485

  Iughetti, Lorenzo ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LIVER ENZYME; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; SIMVASTATIN; TRIACYLGLYCEROL;

ATHEROGENESIS; ATHEROSCLEROSIS; CANCER MORTALITY; CANCER RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHILD; CIGARETTE SMOKING; CLINICAL PRACTICE; DIET RESTRICTION; DISEASE COURSE; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; DRUG SAFETY; DYSLIPIDEMIA; FAMILIAL HYPERCHOLESTEROLEMIA; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; LIFESTYLE MODIFICATION; LONG TERM CARE; MACROPHAGE; MONOTHERAPY; MORBIDITY; MORTALITY; NOTE; OBESITY; ONSET AGE; PRACTICE GUIDELINE; PRESCRIPTION; PREVALENCE; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK REDUCTION; SCHOOL CHILD; VASCULAR SMOOTH MUSCLE;

EID: 67651052563     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: 10.1515/JPEM.2009.22.6.483     Document Type: Note

References (13)

1. Strong JP, McGill HC Jr. The natural history of aortic atherosclerosis: relationship to race, sex and coronary lesions in New Orleans. Exp Mol Pathol 1963; 52: 1-27.
2. Pathological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Relationship of atherosclerosis in young men to serum lipoprotein cholesterol concentrations and smoking: a preliminary report. JAMA 1990; 264: 3018-3024.
3. Berenson GS, Srinivasan SR, Bao W, Newman WP, Tracy RE, Wattingney WA. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults: the Bogalusa Heart Study. N Engl J Med 1998; 338: 1650-1656. (Pubitemid 28267909)
4. Srinivasan SR, Frontini MG, Xu J, Berenson GS. Utility of childhood non-high-density lipoprotein cholesterol levels in predicting adult dyslipidemia and other cardiovascular risks: the Bogalusa Heart Study. Pediatrics 2006; 118: 201-202. (Pubitemid 46071163)
5. Daniels SR, Greer FR, the Committee on Nutrition. Lipid screening and cardiovascular health in childhood. Pediatrics 2008; 122: 198-208.
6. O'Gorman CS, Higgins MF, O'Neill MB. Systematic review and metaanalysis of statins for heterozygous familial hypercholesterolemia in children: evaluation of cholesterol changes and side effects. Pediatr Cardiol 2009; DOI 10.1007/s00246-008-9364-3.
7. Dujovne CA, Ettinger MP, McNeer JF, Lipka LJ, LeBeaut AP, Suresh R, et al. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol 2002; 90: 1092-1097. (Pubitemid 35335597)
8. Davis HR Jr, Basso F, Hoos LM, Tetzloff G, Lally SM, Altmann SW. Cholesterol homeostasis by the intestine: lessons from Niemann-Pick C1 Like 1 (NPC1L1). Atheroscler Suppl 2008; 9: 77-81.
9. Knopp RH, Gitter H, Truitt T, et al. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J 2003; 24: 729-741. (Pubitemid 36458985)
10. Yeste D, Chacón P, Clemente M, Albisu MA, Gussinyé M, Carrascosa A. Ezetimibe as monotherapy in the treatment of hypercholesterolemia in children and adolescents. J Pediatr Endocrinol Metab 2009; 22: 487-492.
11. Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, Visseren FL, Sijbrands EJ, Trip MD, Stein EA, Gaudet D, Duivenvoorden R, Veltri EP, Marais AD, de Groot E, ENHANCE Investigators. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008; 358: 1431-1443.
12. Musunuru K, Blumenthal RS. The implications of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression Trial: a return to first principles. Clin Cardiol 2008; 31: 288-290. (Pubitemid 351961242)
13. Alsheikh-Ali A, Maddukuri PV, Han H, Karas RH. Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer. J Am Coll Cardiol 2007; 50: 409-418.